Underlying causes of cryptogenic stroke and TIA in the nordic atrial fibrillation and stroke (NOR-FIB) study - the importance of comprehensive clinical evaluation

BMC Neurol. 2023 Mar 21;23(1):115. doi: 10.1186/s12883-023-03155-0.

Abstract

Background: Cryptogenic stroke is a heterogeneous condition, with a wide spectrum of possible underlying causes for which the optimal secondary prevention may differ substantially. Attempting a correct etiological diagnosis to reduce the stroke recurrence should be the fundamental goal of modern stroke management.

Methods: Prospective observational international multicenter study of cryptogenic stroke and cryptogenic transient ischemic attack (TIA) patients clinically monitored for 12 months to assign the underlying etiology. For atrial fibrillation (AF) detection continuous cardiac rhythm monitoring with insertable cardiac monitor (Reveal LINQ, Medtronic) was performed. The 12-month follow-up data for 250 of 259 initially included NOR-FIB patients were available for analysis.

Results: After 12 months follow-up probable stroke causes were revealed in 43% patients, while 57% still remained cryptogenic. AF and atrial flutter was most prevalent (29%). In 14% patients other possible causes were revealed (small vessel disease, large-artery atherosclerosis, hypercoagulable states, other cardioembolism). Patients remaining cryptogenic were younger (p < 0.001), had lower CHA2DS2-VASc score (p < 0.001) on admission, and lower NIHSS score (p = 0.031) and mRS (p = 0.016) at discharge. Smoking was more prevalent in patients that were still cryptogenic (p = 0.014), while dyslipidaemia was less prevalent (p = 0.044). Stroke recurrence rate was higher in the cryptogenic group compared to the group where the etiology was revealed, 7.7% vs. 2.8%, (p = 0.091).

Conclusion: Cryptogenic stroke often indicates the inability to identify the cause in the acute phase and should be considered as a working diagnosis until efforts of diagnostic work up succeed in identifying a specific underlying etiology. Timeframe of 6-12-month follow-up may be considered as optimal.

Trial registration: ClinicalTrials.gov Identifier NCT02937077, EudraCT 2018-002298-23.

Keywords: Atrial fibrillation; Cryptogenic stroke; Guidelines; Insertable cardiac monitor; Secondary prevention; Stroke cause.

Publication types

  • Observational Study
  • Multicenter Study

MeSH terms

  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / epidemiology
  • Causality
  • Electrocardiography, Ambulatory / adverse effects
  • Humans
  • Ischemic Attack, Transient* / complications
  • Ischemic Attack, Transient* / diagnosis
  • Ischemic Attack, Transient* / epidemiology
  • Ischemic Stroke* / complications
  • Stroke* / diagnosis
  • Stroke* / epidemiology
  • Stroke* / etiology

Associated data

  • ClinicalTrials.gov/NCT02937077